Stockholm, Sweden, October 21, 2026. Egetis Therapeutics AB (publ) (NASDAQ Stockholm: EGTX) today announced the composition of the Nomination Committee for the 2027 Annual General Meeting (AGM) to be held on May 12, 2027.
The Nomination Committee, which has been appointed in accordance with the principles adopted by the Annual General Meeting held on April 14, 2026, comprises the following members:
James Brush, appointed by Frazier Life Sciences
Peter Lindell, appointed by Cidro Förvaltning AB
Peder Walberg, appointed by Cetoros AB
Mats Blom, Chairman of the Board of Directors, will co-opt to the Nomination Committee.
The Committee's assignment is to present proposals regarding Chairman and other members of the Board, as well as remuneration to the Board´s members, to the AGM. The Nomination Committee shall also submit proposals for appointment and remuneration of auditors. Further, the Committee shall submit proposals regarding the process to appoint the Nomination Committee to the AGM in 2028.
Shareholders who wish to submit proposals to the Nomination Committee can do so by email to [email protected] (please label emails ‘Nomination Committee’). Proposals should be submitted no later than January 22, 2027.
